ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

ClinicalTrials.gov ID: NCT06453044

Public ClinicalTrials.gov record NCT06453044. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 3:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Mosunetuzumab With Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma

Study identification

NCT ID
NCT06453044
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
City of Hope Medical Center
Other
Enrollment
41 participants

Conditions and interventions

Interventions

  • Biospecimen Collection Procedure
  • Computed Tomography Procedure
  • Magnetic Resonance Imaging Procedure
  • Mosunetuzumab Biological
  • Polatuzumab Vedotin Drug
  • Positron Emission Tomography Procedure
  • Questionnaire Administration Other

Procedure · Biological · Drug + 1 more

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 8, 2024
Primary completion
Mar 13, 2028
Completion
Mar 13, 2028
Last update posted
Sep 23, 2025

2024 – 2028

United States locations

U.S. sites
2
U.S. states
1
U.S. cities
2
Facility City State ZIP Site status
City of Hope Medical Center Duarte California 91010 Recruiting
City of Hope Orange County Lennar Foundation Cancer Center Irvine California 92618 Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06453044, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 23, 2025 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06453044 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →